Feb 12 (Reuters) - CSL Ltd (CSL) :
- TOP-LINE RESULTS FROM PHASE 3 AEGIS-II TRIAL EVALUATING EFFICACY AND SAFETY OF CSL112
- THERE WERE NO MAJOR SAFETY OR TOLERABILITY CONCERNS WITH CSL112
- STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$254.86 |
Change
6.465(2.60%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $256.17 | $251.10 | $208.7M | 809.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 42 | $254.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $254.88 | 8 | 2 |
View Market Depth
| Last trade - 11.51am 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |